Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech's Acquisition Of Tanox Does Not Represent A Strategic Shift, CEO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Genentech will continue to set a "high bar" for acquisitions after buying Xolair partner Tanox for $919 mil., firm says.

You may also be interested in...



Genentech Product Sales Rise 18 Percent, Led By Avastin, Though Lucentis A Disappointment

Firm would bid on remaining rights to Rituxan should a change of control occur at Biogen Idec, CFO Ebersman says during third quarter call .

Genentech Product Sales Rise 18 Percent, Led By Avastin, Though Lucentis A Disappointment

Firm would bid on remaining rights to Rituxan should a change of control occur at Biogen Idec, CFO Ebersman says during third quarter call .

Genentech’s Tanox Acquisition Delayed Due to FTC Information Request

Firms expect $919 million deal to close by mid-year.

Related Content

Topics

UsernamePublicRestriction

Register

PS063351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel